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Abstract
Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the 
proportion of rifampicin-resistant isolates that were isoniazid-susceptible by phenotypic drug-
susceptibility tests varied widely (0.5%–11.6%). Rifampicin-resistant isolates that were isoniazid-
susceptible had significantly lower rates of resistance to other first-line and second-line anti-TB 
drugs (except rifabutin) compared to multidrug-resistant isolates. Rifampicin resistance is not 
always a good proxy for a presumptive diagnosis of multidrug-resistant tuberculosis, which has 
implications for use of molecular assays that identify only rifampicin resistance-associated DNA 
mutations.
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Molecular tests greatly expedited the detection of M. tuberculosis complex (MTB) and 
rifampicin (RMP) resistance. Recently WHO endorsed use of an automated rapid molecular 
assay Xpert® MTB/RIF for the detection of MTB and RMP-resistance.1 RMP-resistance is 
frequently associated with concomitant isoniazid (INH) resistance,2 and thus is considered 
by many to be a proxy for multidrug-resistant (MDR) tuberculosis (TB); however, this 
association may vary widely between countries and patient groups.3 The WHO/IUATLD 
Global Project on Anti-tuberculosis Drug Resistance Surveillance (Global Project)2, 4–6 
documented a low overall prevalence of non-MDR RMP-resistance using as a denominator 
all TB cases, but little has been evaluated about the proportion of RMP-resistant isolates that 
are INH-susceptible using as a denominator all RMP-resistant cases. This latter proportion 
should be assessed when considering use of RMP-resistance as a proxy for MDR-TB.
Global Project data demonstrates that the proportion of RMP-resistant isolates that are INH-
susceptible can be substantial, >40% of new cases in low MDR-TB prevalence settings, but 
even in high MDR-TB burden settings ~14% of new RMP-resistant cases remain INH-
susceptible.7 Preliminary results of an analysis of U.S. TB surveillance data indicates 22% 
of reported RMP-resistant isolates are INH-susceptible.8 An Xpert® MTB/RIF 
implementation study demonstrated that even among MDR-TB suspect patients, 6.8% of 
RMP-resistant cases were INH-susceptible.9 Treating all RMP-resistant patients as though 
they have MDR-TB would deprive the INH-susceptible cases of one of the most effective 
bactericidal and least expensive TB drugs. Furthermore, little is known about the association 
between RMP-resistance and second-line drug resistance, especially when isolates are INH-
susceptible. A better understanding of these issues is urgent to guide recommendations for 
treatment of patients with RMP-resistance found by any molecular method such as the 
Xpert® MTB/RIF.
To address these questions, we analyzed drug-susceptibility test (DST) results from a 
collaborative study by the U.S. Centers for Disease Control and Prevention, the WHO and 
the Supranational Reference Laboratories (SRLs).10 Our objectives were to (1) describe the 
proportion of MTB RMP-resistant isolates that are susceptible to INH by geographic region, 
and (2) compare proportions of resistance to other first-line and second-line drugs between 
RMP-resistant/INH-susceptible and MDR-TB isolates.
The study
We conducted a retrospective analysis of data reported from 14 SRLs, representing cultures 
from 112 TB laboratories in 80 countries, including phenotypic DST results for MTB 
isolates that had been tested for resistance to first-line and second-line drugs during 2000–
2004.10
The SRL in the Republic of Korea routinely performs DSTs to first-line and second-line 
drugs on all initial culture-positive TB isolates in the country, thus data were considered to 
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be representative of TB in Korea. Data from the other 13 SRLs included isolates from their 
own and other countries that were submitted for various purposes, including clinical 
confirmation, surveillance, and quality assurance; specimens from those SRLs were 
considered a convenience sample biased toward a higher prevalence of MDR. For this 
reason, we distinguish DST results from Korea and the other SRLs.
In total, 17,946 isolates were included in analysis, 3,851 (21.5%) were resistant to RMP; 
292/3,851 (7.6%) were INH-susceptible (Table 1). The proportion of all RMP-resistant 
isolates that were INH-susceptible ranged from 0.5% in Northern Africa/Middle East to 
11.6% of isolates from Korea. Isolates that were RMP-resistant/INH-susceptible had 
significantly lower rates of resistance to other first-line and second-line drugs (except 
rifabutin) compared to MDR-TB isolates (Table 2).
Conclusions
We found that the proportion of INH-susceptibility among isolates with RMP-resistance 
varied by region and this proportion could depend on whether the samples were 
representative or “convenience”. RMP-resistant/INH-susceptible isolates were significantly 
more likely to be susceptible to all other anti-TB drugs tested (except rifabutin) compared to 
MDR-TB isolates.
The reliability of using molecular testing for RMP-resistance to diagnose MDR-TB will be 
driven by two components: the positive predictive value (PPV) of RMP-resistance as 
detected by the assay (which is tied to local prevalence of RMP-resistance, sensitivity and 
specificity), and the proportion of RMP-resistant isolates that are INH-resistant. Therefore, 
PPV of RMP-resistance will be diminished in countries/settings with a low prevalence of 
MDR-TB or among low MDR-TB risk patient groups. Targeted molecular testing of high 
MDR-TB risk groups should increase pre-test probability and improve PPV. On the other 
side, our and other7 data suggest that in certain countries/settings among patients with a high 
a priori probability of MDR-TB, RMP-resistance may be a reliable proxy marker for MDR. 
Further, our analysis suggests that in patients with RMP-resistant TB, INH susceptibility 
may correlate with susceptibility to other anti-TB drugs, and this knowledge might help in 
planning more effective treatment regimens.
Our analysis has limitations. We did not have information about the reasons that isolates 
were submitted to the SRL; however, it is likely this represents a sampling bias, given the 
greater probability of MDR-TB; thus, our results probably underestimate the proportion of 
RMP-resistant/INH-susceptible isolates. We did not have information on previous TB 
treatment history, thus we could not stratify resistance rates for new and re-treatment cases. 
No clinical information was provided, including HIV status of patients; in some areas DST 
is more often done in HIV-infected TB patients and it was previously shown that in some 
settings RMP-resistance/INH-susceptibility is associated with HIV-infection.8, 11 Lastly, 
conventional growth-based DST is imperfect, and underscores the increasing need to 
adjudicate results with genetic data.
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Despite these limitations, our analysis provides data important for implementation and use 
of rapid molecular tests for RMP-resistance. Additional research focused on regional 
epidemiology of drug-resistant TB; association between RMP-resistance, MDR and second-
line drug resistance; and between RMP-resistance and HIV status in specific settings will 
ensure optimal use of rapid RMP-resistance testing. DST to other drugs including INH 
should be done if RMP-resistance is detected. If a substantial proportion of RMP-resistant 
TB is INH-susceptible in a given population, including INH in empiric treatment regimens 
triggered by RMP-resistance may be superior to omitting. Research is needed to compare 
outcomes and costs of treatment of RMP-resistant/INH-susceptible and MDR-TB. Rapid 
molecular tests for MTB and RMP-resistance are much anticipated, potentially revolutionary 
advances in the fight against MDR-TB, and much needed operations research will help 
maximize their impact.
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Table 1
Isoniazid (INH) susceptibility among rifampicin (RMP)-resistant isolates, by geographic region, 2000–2004£
Geographic region Isolates with any resistance to RMP/Total 
isolates tested (%)
INH susceptibility among isolates with any 
RMP resistance
Susceptible to INH Resistant to INH 
(MDR-TB*)
n/N (%) n (%) n (%)
Republic of Korea 1,469/11,939 (12.3) 171 (11.6) 1,298 (88.4)
Latin America¥ 508/799 (63.6) 39 (7.7) 469 (92.3)
Industrialized nations¥¥ 869/2,709 (32.1) 61 (7.0) 808 (93.0)
Sub-Saharan Africa** 89/373 (23.9) 6 (6.7) 83 (93.3)
Asia (except Republic of Korea) † 284/389 (73.0) 8 (2.8) 276 (97.2)
Eastern Europe†† 430/1,178 (36.5) 6 (1.4) 424 (98.6)
Northern Africa and Middle 
East***
202/559 (36.1) 1 (0.5) 201 (99.5)
Total 3,851/17,946 (21.5) 292 (7.6) 3,559 (92.4)
£
All reported drug susceptibility test results are based on phenotypic culture-based methods.10
*
MDR-TB was defined as resistance to at least INH and RMP.
¥
Argentina, Bolivia, Brazil, Chile, Costa Rica Ecuador, El Salvador, Guatemala, Guyana, French Guyana, Mexico, Peru.
¥¥
Australia, Belgium, Canada, Germany, France, Ireland, Portugal, Spain, United Kingdom, USA.
**
Botswana, Burundi, Cameroon, Central African Republic, Cote d’Ivoire, Kenya, Madagascar, Rwanda, South Africa, Senegal, Uganda.
†
Bangladesh, Fiji, Indonesia, Papua New Guinea, Thailand, East Timor.
††
Azerbaijan, Armenia, Czech Republic, Republic of Georgia, Kazakhstan, Russia.
***
Afghanistan, Algeria, Egypt, Tunisia, Djibouti.
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